Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 9Multiple Myeloma 6Glioma 6Neoplasm Metastasis 5Lymphoma 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neurofibromatosis 1 4Pancreatic Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Thyroid Neoplasms 2Neurofibroma, Plexiform 2Lung Neoplasms 2Leukemia, Myelomonocytic, Juvenile 2Glioblastoma 2Brain Neoplasms 2Astrocytoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Sarcoma 1Refractory Differentiated Thyroid Gland Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Gemcitabine 6Cisplatin 6pembrolizumab 3durvalumab 3Oxaliplatin 3tivozanib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2trametinib 1tislelizumab 1olaparib 1atezolizumab 1Yttrium-90 1Stents 1Radiosurgery 1Nivolumab 1Leucovorin 1Ipilimumab 1Folfox protocol 1Fluorouracil 1Floxuridine 1Dexamethasone 1Capecitabine 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × trametinib × 90 days × Clear all
NCT05874414 2026-05-14

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Genfit

Phase 1/2 Recruiting
74 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡